Jun

    Europe's Take On Excessive Pricing: Recent Enforcement Practice in Italy and the UK

    12 PM EDT

    Last year saw antitrust investigations into allegations of abusive “excessive pricing” in Italy, the UK and elsewhere. In November 2016, the Italian authority fined Aspen Holdings USD 6m for allegedly increasing the price of cancer drugs by up to 1,500% and in December 2016, the UK fined Pfizer and its distributor over USD 110m for an alleged 2,600% price increase for an epilepsy drug. On 3 May 2017, the European consumer body asked Competition Commissioner Vestager whether the pricing practices of some pharmaceutical companies constituted an abusive of a dominant position. This panel of UK/Italian enforcers describes recent enforcement practice, and when antitrust should intervene.

    FREE: Antitrust Section Members, Government, Non-profit Employees, Students. $25 Other Non-Members

    Explore Section benefits or call 1-800-285-2221 to join. Code RAT14IP25. For this and all upcoming events visit http://ambar.org/atevents.

    CLE: The ABA is not seeking CLE credit for this program.

    Audio Archive: Provided all releases are obtained, MP3 recordings of this program will be available to Section members on the Committee Program Audio page.

     


     

    $25
    NON-MEMBERS
    $10
    MEMBERS
    $0
    SECTION MEMBERS
    Register Now *Additional discounts may apply at checkout

    Log In to view your rate

    Europe's Take On Excessive Pricing: Recent Enforcement Practice in Italy and the UK

    Event Details

    Format

    Teleconference

    Date

    Jun 12, 2017

    2017-06-12T12:00:00-04:00 2017-06-12T13:00:00-04:00 Europe's Take On Excessive Pricing: Recent Enforcement Practice in Italy and the UK

    Last year saw antitrust investigations into allegations of abusive “excessive pricing” in Italy, the UK and elsewhere. In November 2016, the Italian authority fined Aspen Holdings USD 6m for allegedly increasing the price of cancer drugs by up to 1,500% and in December 2016, the UK fined Pfizer and its distributor over USD 110m for an alleged 2,600% price increase for an epilepsy drug. On 3 May 2017, the European consumer body asked Competition Commissioner Vestager whether the pricing practices of some pharmaceutical companies constituted an abusive of a dominant position. This panel of UK/Italian enforcers describes recent enforcement practice, and when antitrust should intervene.

    FREE: Antitrust Section Members, Government, Non-profit Employees, Students. $25 Other Non-Members

    Explore Section benefits or call 1-800-285-2221 to join. Code RAT14IP25. For this and all upcoming events visit http://ambar.org/atevents.

    CLE: The ABA is not seeking CLE credit for this program.

    Audio Archive: Provided all releases are obtained, MP3 recordings of this program will be available to Section members on the Committee Program Audio page.

     


     

    Speakers

    Leanne Graveney

    Competition and Markets Authority

    Lourenco Ventura

    Competition and Markets Authority

    Sponsors

    Health Care and Pharmaceuticals Committee

    Section of Antitrust Law

    Moderators

    Related Products

    Related On-Demand CLE